What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Insilico Medicine
Applies generative AI to discover new drug candidates and identify novel disease targets.
What they do
Insilico Medicine utilizes deep generative models and reinforcement learning to accelerate drug discovery. The company offers end to end software platforms for target identification, molecular generation, and clinical trial outcome prediction to pharmaceutical and biotechnology companies globally.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Hong Kong, China
- Region
- Asia-Pacific
- Founded
- 2014
- Total funding
- $401M raised
Notable investors: Warburg Pincus, B Capital Group, Qiming Venture Partners, Deerfield Management.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA